Fluorobiotech is proud to announce that, in collaboration with the Stellenbosch University Biofoundry, we have been awarded a landmark € 350 thousand grant to help expand local vaccine production capabilities by advancing local production of critical enzymes for mRNA vaccine manufacturing.
Our mission: to build a self-reliant, scalable, and sustainable African platform for enzyme manufacturing—supporting local vaccine- and therapeutic-production.
As part of this effort, Fluorobiotech will deploy our proprietary SelfPrep technology to manufacture high-performance molecular enzymes at industrial scale. In parallel, our partners at the Stellenbosch University Biofoundry will develop and automate enzyme quality control assays and innovate around enzyme formulations, helping to build resilience into the regional vaccine supply chain.
Together, we are tackling supply chain vulnerabilities, reducing dependency on imports, and accelerating the transition to GMP-grade, locally produced mRNA vaccine raw materials. This partnership is laying the groundwork for long-term biomanufacturing resilience, cost reduction, and African-owned IP in biotechnology.
We are deeply grateful to all partners and stakeholders helping turn this vision into reality.
This transformative initiative is made possible through the generous support of the Bundesministerium für wirtschaftliche Zusammenarbeit und Entwicklung (BMZ) and the European Union Delegation to South Africa, delivered through the GIZ SAVax Programme, GIZ South Africa, Lesotho & eSwatini, in partnership with the Department of Science, Technology and Innovation. This initiative forms part of the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies (TEI MAV+) in Africa.
